MX2023004829A - Compuestos, composiciones y metodos de uso para tratar fusiones espinales. - Google Patents

Compuestos, composiciones y metodos de uso para tratar fusiones espinales.

Info

Publication number
MX2023004829A
MX2023004829A MX2023004829A MX2023004829A MX2023004829A MX 2023004829 A MX2023004829 A MX 2023004829A MX 2023004829 A MX2023004829 A MX 2023004829A MX 2023004829 A MX2023004829 A MX 2023004829A MX 2023004829 A MX2023004829 A MX 2023004829A
Authority
MX
Mexico
Prior art keywords
methods
compounds
compositions
treat spinal
spinal fusions
Prior art date
Application number
MX2023004829A
Other languages
English (en)
Spanish (es)
Inventor
Philip S Low
Stewart Low
Jeffery Nielsen
Original Assignee
Purdue Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Purdue Research Foundation filed Critical Purdue Research Foundation
Publication of MX2023004829A publication Critical patent/MX2023004829A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0032—Methine dyes, e.g. cyanine dyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0056—Peptides, proteins, polyamino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
MX2023004829A 2020-10-26 2021-08-26 Compuestos, composiciones y metodos de uso para tratar fusiones espinales. MX2023004829A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063105678P 2020-10-26 2020-10-26
US202163193753P 2021-05-27 2021-05-27
PCT/US2021/047827 WO2022093374A1 (en) 2020-10-26 2021-08-26 Compounds,compositions and methods of use to treat spinal fusions

Publications (1)

Publication Number Publication Date
MX2023004829A true MX2023004829A (es) 2023-07-18

Family

ID=81383097

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023004829A MX2023004829A (es) 2020-10-26 2021-08-26 Compuestos, composiciones y metodos de uso para tratar fusiones espinales.

Country Status (7)

Country Link
US (1) US20230390363A1 (enExample)
EP (1) EP4232075A4 (enExample)
JP (1) JP2023547889A (enExample)
AU (1) AU2021369193A1 (enExample)
CA (1) CA3196688A1 (enExample)
MX (1) MX2023004829A (enExample)
WO (1) WO2022093374A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3796941A4 (en) 2018-05-30 2022-12-28 Purdue Research Foundation Targeting anabolic drugs for accelerated fracture repair
MX2023004796A (es) * 2020-10-26 2023-07-18 Purdue Research Foundation Compuestos, composiciones y metodos de uso para tratar fracturas oseas.
WO2024246840A1 (en) * 2023-06-01 2024-12-05 Radius Health, Inc. Methods for identification and quantitation of abaloparatide and related peptide impurities

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL266977B2 (en) * 2016-11-30 2024-01-01 Purdue Research Foundation Fracture-targeted bone regeneration using thyroid hormone receptor stimulation
EP3765488A1 (en) * 2018-03-12 2021-01-20 Fresenius Kabi iPSUM S.r.l. Process for the manufacture of pthrp analogue
EP3796941A4 (en) * 2018-05-30 2022-12-28 Purdue Research Foundation Targeting anabolic drugs for accelerated fracture repair
MX2023004796A (es) * 2020-10-26 2023-07-18 Purdue Research Foundation Compuestos, composiciones y metodos de uso para tratar fracturas oseas.

Also Published As

Publication number Publication date
CA3196688A1 (en) 2022-05-05
WO2022093374A1 (en) 2022-05-05
US20230390363A1 (en) 2023-12-07
WO2022093374A8 (en) 2022-09-29
AU2021369193A1 (en) 2023-06-01
EP4232075A1 (en) 2023-08-30
EP4232075A4 (en) 2024-12-18
JP2023547889A (ja) 2023-11-14

Similar Documents

Publication Publication Date Title
MX2024006824A (es) Degradadores de la proteina transductora de se?al y activadora de la transcripcion 3 (stat3) y usos de los mismos.
PH12020550901A1 (en) Macrocyclic compounds for treating disease
CO2022019316A2 (es) Inhibidores alostéricos de egfr y métodos de uso de estos
BR112018008326A2 (pt) composições e métodos para o tratamento de câncer
PH12021551409A1 (en) Kif18a inhibitors
EA201890725A1 (ru) Агонисты фарнезоидного х-рецептора и их применение
MX2019010040A (es) Composiciones y métodos para el tratamiento del cáncer.
CO2021002977A2 (es) Dimetilaminoazetidinaminas como inhibidores de jak
SG10201811841UA (en) Methods of treating cancer using tigit inhibitors and anti-cancer agents
MX2022008523A (es) Compuestos que interactuan con glicanos y metodos de uso.
EA201791018A1 (ru) Производные 6-амино-7-бицикло-7-деазапурина в качестве ингибиторов протеинкиназы
MX388013B (es) Compuestos y usos de estos para la modulación de la hemoglobina.
MX2016010504A (es) Metodos para el tratamiento de pacientes con hipercolesterolemia que no esta controlada adecuadamente por una terapia con estatinas de dosis moderada referencia cruzada a solicitudes relacionas.
EA201892225A1 (ru) АНТИТЕЛА К ФАКТОРУ Bb КОМПЛЕМЕНТА И ИХ ПРИМЕНЕНИЕ
EA202090741A1 (ru) Конъюгаты антитела к тканевому фактору и лекарственного средства и их применение в лечении рака
BR112016016870A8 (pt) derivados de icariina, seus usos, e composição farmacêutica
MX2024012294A (es) RECEPTORES DE TGF-ß Y MÉTODOS DE USO
MX2023004796A (es) Compuestos, composiciones y metodos de uso para tratar fracturas oseas.
MX2017014715A (es) Benzamidas sustituidas y metodos para utilizarlas.
TN2018000372A1 (en) Tetrahydropyrimidodiazepine and tetrahydropyridodiazepine compounds for treating pain and pain related conditions.
MX385698B (es) Uso de un compuesto que comprende un grupo pirrolidinilo y pirimidinilo para tratar enfermedades oculares
CO2022006466A2 (es) Inhibidores de egfr alostéricos y métodos de uso de los mismos
GEAP202516674A (en) Indazole macrocycles and their use
PH12022551371A1 (en) Macrocycles for use in treating disease
MX2024005649A (es) Proteinas quimericas basadas en sirp1a y cd40l.